🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Newly Diagnosed Multiple Myeloma

Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma NCT06182774Phase 331 sites📍 Edmonton📍 Kelowna📍 Vancouver Canadian Cancer Trials Group · Tests: Daratumumab, Lenalidomide, Dexamethasone, Isatuximab MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma NCT07106736Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: BCMA CAR-T, GPRC5D/CD3 BiTEs Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure NCT07085728Phase 21 site📍 Anchorage Eastern Cooperative Oncology Group · Tests: Cyclophosphamide, Bortezomib (VELCADE), Dexamethasone, Daratumumab-hyaluronidase Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple Myeloma NCT07891923Phase 22 sites📍 Navi Mumbai📍 Navi Mumbai Tata Memorial Centre · Tests: Daratumumab (Intravenously) with VRd (Bortezomib, Lenalidomide, and Dexamethasone) A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL). NCT07638683Phase 21 site📍 Shanghai Shanghai Zhongshan Hospital · Tests: Teclistamab MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma NCT07409454Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: anti-BCMA/CD3 bispecific antibody Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE) NCT06993675Phase 22 sites📍 New Haven📍 Rochester Noffar Bar · Tests: Talquetamab, Teclistamab Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma NCT05145400Phase 25 sites📍 Chapel Hill📍 Charlotte📍 Durham UNC Lineberger Comprehensive Cancer Center · Tests: Isatuximab, Lenalidomide, Dexamethasone IMMUNOPLANT for Newly Diagnosed Multiple Myeloma NCT06376526Phase 21 site📍 Miami Dickran Kazandjian, MD · Tests: Linvoseltamab A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment NCT05828511Phase 1, Phase 232 sites📍 Los Angeles📍 Orange📍 Denver Regeneron Pharmaceuticals · Tests: Linvoseltamab Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma NCT07652138Phase 11 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: BCMA/CD19-targeted allogeneic CAR-T Selinexor and Backbone Treatments of Multiple Myeloma Patients NCT02343042Phase 1, Phase 225 sites📍 Gilbert📍 Los Angeles📍 Denver Karyopharm Therapeutics Inc · Tests: Selinexor, Dexamethasone, Lenalidomide, Pomalidomide, Bortezomib A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant NCT07095452Phase 2, Phase 349 sites📍 Scottsdale📍 Los Angeles📍 Denver AbbVie · Tests: Etentamig, Lenalidomide, Daratumumab, Dexamethasone, Dexamethasone BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma NCT06793449Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: anti-BCMA CAR-T, ASCT Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level NCT07649525Phase 35 sites📍 Bristol📍 Eastbourne📍 Leeds University of Leeds · Tests: Daratumumab, Lenalidomide, Dexamethasone, Teclistamab, Talquetamab Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma NCT05091372Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Belantamab mafodotin, Lenalidomide ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma NCT07106710Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: Autologous Hematopoietic Stem Cell Transplantation, BCMA CAR-T, GPRC5D/CD3 BiTEs Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma NCT07285239Phase 31 site📍 La Crosse PrECOG, LLC. · Tests: Arm A: Belantamab Mafodotin, Arm B: Daratumumab Hyaluronidase, Bortezomib, Lenalidomide, Dexamethasone Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients NCT06918002Phase 369 sites📍 Brussels📍 Brussels📍 Charleroi Intergroupe Francophone du Myelome · Tests: Elranatamab, Lenalidomide (Revlimid®), Daratumumab SC (Darzalex), Autologous Stem Cell Transplantation, Bortezomib (Vel… Individualized Dynamic Frailty-tailored Therapy (DynaFiT) in Elderly Patients With NDMM NCT06099912n/a1 site📍 Changchun FengYan Jin A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma NCT07477587Phase 184 sites📍 Springdale📍 Jacksonville📍 Margate Shanghai Henlius Biotech · Tests: HLX15-SC-Rd, US-DARZALEX FASPRO®-Rd Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma NCT06974786Phase 211 sites📍 Birmingham📍 Denver📍 Iowa City SCRI Development Innovations, LLC · Tests: Elranatamab, Daratumumab, Lenalidomide, autologous stem cell transplantation CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment NCT07585760Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: CM336 Plus Isatuximab A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma NCT06497738n/a6 sites📍 Changzhou📍 Nanjing📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant NCT07297329Phase 31 site📍 Beijing Sinocelltech Ltd. · Tests: SCTC21C, Bortezomib, Lenalidomide, Dexamethasone GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 NCT05695508Phase 211 sites📍 Berlin📍 Chemnitz📍 Dresden University of Heidelberg Medical Center · Tests: Teclistamab (Tec), Daratumumab, Dexamethasone, Lenalidomide, Bortezomib Exercise Phenotyping Prior to Chemotherapy in Newly Diagnosed Multiple Myeloma (MM-Exercise) NCT07851493n/a1 site📍 Munich Technical University of Munich A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma NCT05552222Phase 3270 sites📍 Gilbert📍 Tucson📍 Clovis Janssen Research & Development, LLC · Tests: Teclistamab, Daratumumab, Lenalidomide, Dexamethasone, Talquetamab Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients NCT05272826Phase 27 sites📍 Edmonton📍 St. John's📍 Halifax Canadian Myeloma Research Group · Tests: Iberdomide, Bortezomib, Dexamethasone, Isatuximab Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients NCT06682156n/a1 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: Carfilzomib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy